biomedicina slovenica

pr=Čufer : 382-481

  1. Paridaens R; Therasse P; Dirix L; Beex L; Piccart M; Cameron D; Čufer T; Roozendaal K; Nooij M; Mattiacci M-R
    First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts) - A randomized phase III trial of the EORTC breast group
    2004 ►
  2. Bottomley Andrew; Biganzoli Laura; Čufer Tanja; Coleman Robert E; Coens Cornel; Efficace Fabio; Calvert Hilary Allan; Gamucci Teresa; Twelves Chris; Fargeot Pierre; Piccart Martine
    Randomized, controlled trial investigating short-term health-related quality of life with doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: European organization for research and treatment of cancer breast cancer group, Investigational drug branch for breast cancer and the New drug development group study
    2004 ►
  3. Kocijančič I; Kocijančič K; Čufer T
    Imaging of pleural fluid in healthy individuals
    2004 ►
  4. Reberšek Martina; Čufer Tanja; Čemažar Maja; Kranjc Simona; Serša Gregor
    Electrochemotherapy with cisplatin of cutaneous tumor lesions in breast cancer
    2004 ►
  5. Pajk B; Borštnar S; Snoj Nataša; Čufer T
    Tumorske značilnosti in preživetje brez znamenj bolezni (PBZB) bolnic z rakom dojke starejših od 70 let v primerjavi z mlajšimi bolnicami
    2004 ►
  6. Borštnar Simona; Čufer Tanja; Pajk Bojana
    Rak dojke: kaj morate vedeti
    2004 ►
  7. Atalay G; Dirix L; Biganzoli L; Beex L; Nooij M; Cameron D; Lohrisch C; Čufer T; Lobelle JP; Mattiaci MR
    The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients'
    2004 ►
  8. Piškur Peter; Sonc Monika; Čufer Tanja; Borštnar Simona; Mrhar Aleš
    Pharmacoeconomic aspects of adjuvant early breast cancer (EBC) treatment in postmenopausal women with anastrozole (A) or tamoxifen (T): Slovenian perspective
    2004 ►
  9. Look Maxime; van Putten Vim; Duffy Michael; Harbeck Nadia; Christensen Ib Jarle; Thomssen Christoph; Kates Ronald; Spyratos Frederique; Čufer Tanja; Borštnar Simona
    Pooled analysis of prognostic impact of uPA and PAI-I in breast cancer patients
    2003 ►
  10. Paridaens R; Therasse P; Dirix L; Beex L; Piccart MJ; Cameron D; Čufer T; Roozendael K; Nooy M; Mattiacci MR
    First results of a randomized phase III trial comparing exemestane versus tamoxifen as first-line hormone therapy (HT) for postmenopausal women with metastatic breast cancer (MBC) - EORTC 10951 in collaboration with the exemestane working group and NCIC clinical trials group
    2004 ►
  11. Matos E; Borstnar S; Vrhovec I; Svetič B; Čufer T
    PAI-1 and PAI-2 as predictive factors in breast cancer
    2004 ►
  12. Drev P; Golouh R; Snoj Nataša; Čufer T
    Correlation between Her-2 status in primary tumour and response to anastrozole in patients with metastatic breast cancer
    2004 ►
  13. Pajk B; Borštnar S; Snoj Nataša; Čufer T
    Disease free survival (DFS) in breast cancer patients older than 70 years compered to younger patients groups
    2004 ►
  14. Paridaens R; Dyczka J; Rutgers EJT; Coleman R; Čufer T; Jassem J; Nortier JRW; Morales L; Mattiacci MR; Therasse P; Gasthuisberg UZ
    Postoperative adjuvant chemotherapy folowed by adjuvant tamoxifen versus nil for patients with operable breast cancer. First results of a randomized phase III trial EORTC 10901
    2004 ►
  15. Snoj Nataša; Pajk B; Borštnar S; Čufer T
    The benefits of adjuvant hormonal therapy in patients with early breast cancer 35 years old or younger
    2004 ►
  16. Piškur P; Sonc M; Čufer T; Borštnar S; Mrhar A
    Pharmacoeconomics aspects of adjuvant early breast cancer treatment in postmenopausal women with anastrozole or tamoxifen: a Slovenian perspective
    2004 ►
  17. Čufer Tanja
    Generična in medsebojno zamenljiva zdravila v onkologiji
    2003 ►
  18. Čufer Tanja
    Biološko zdravljenje
    2004 ►
  19. Čufer Tanja
    Bolniku vedno povedati resnico
    2004 ►
  20. Kragelj Borut; Sedmak Boris; Borštner Simona; Čufer Tanja
    Vloga obsevanja pri zdravljenju lokaliziranega raka sečnika
    2004 ►
  21. Čufer Tanja
    Clinical utility of serine proteases in breast cancer
    [Klinična uporabnost serinskih proteaz pri raku dojk]
    2004 ►
  22. Sonc M; Omerza M; Čufer T; Slanc J; Kozjek F
    Pharmacoeconomics of salvage therapy and quality of life in metastatic breast cancer patients
    2003 ►
  23. Atalay G; Biganzoli L; Renard F; Paridaens R; Čufer T; Coleman R; Calvert AH; Gamucci T; Minisini A; Therasse P
    Clinical outcome of breast cancer patients with liver metastases alone in the anthracycline-taxane era: a retrospective analysis of two prospective, randomised metastatic breast cancer trials
    2003 ►
  24. Čufer Tanja
    Clinical utility of serine proteases in breast cancer
    2004 ►
  25. Čufer Tanja
    Rak dojke
    2003 ►
  26. Čufer Tanja
    Imenitna pobuda
    2003 ►
  27. Čufer Tanja
    Dopolnilno sistemsko zdravljenje raka dojk
    [Adjuvant systemic treatment of breast cancer]
    2003 ►
  28. Spataro Vito J; Lamovec J; Jančar J; Nowak J; Eržen D; Naglas M; Senčar M; Červak J; Cerar O; Štabuc B; Šebek S; Čufer T
    Decreased immunoreactivity for p27 protein in patients with early-stage breast carcinoma is correlated with HER-2/neu overexpression and with benefit from one course of perioperative chemotherapy in patients with negative lymph node status: results from International breast study group trial 5
    2003 ►
  29. Paridaens R; Dirix L; Lohrisch C; Beex L; Nooij M; Cameron D; Biganzoli L; Čufer T; Duchateau L; Hamilton A; Lobelle JP; Piccart M
    Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer
    2003 ►
  30. Paridaens R; Dirix L; Beex L; Nooij MN; Čufer T; Lohrisch C; Biganzoli L; van Hoorebeeck I; Duchateau L; Lobelle JP; Piccart M
    Promising results with exemestane in the first-line treatment of metastatic breast cancer: a randomized phase II EORTC trial with a tamoxifen control
    2000 ►
  31. Maillet P; Bonnefoi H; Vaudan-Vutskits G; Pajk B; Čufer T; Foulkes WD; Chappuis PO; Sappino AP
    Constitutional alterations of the ATM gene in early onset sporadic breast cancer
    2002 ►
  32. Therasse P; Mauriac L; Welnicka-Jaskiewicz M; Bruning P; Čufer T; Bonnefoi H; Tomiak E; Pritchard KI; Hamilton A; Piccart MJ
    Final results of a randomized phase III trial comparing cyclophosphamide, epirubicin, and fluorouracil with a dose-intensified epirubicin and cyclophosphamide + filgrastim as neoadjuvant treatment in locally advanced breast cancer: an EORTC-NCIC-SAKK multicenter study
    2003 ►
  33. Bonnefoi H; Biganzoli L; Mauriac L; Čufer T; Schaefer P; Atalay G; Piccart M
    An EORTC phase I study of capecitabine (xeloda) in combination with fixed doses of cyclophosphamide and epirubicin (cex) as primary treatment for large operable or locally advanced/inflammatory breast cancer
    2003 ►
  34. Čufer Tanja; Pajk Bojana
    Sistemska terapija rakave bolezni in njen vpliv na bolnika
    2002 ►
  35. Čufer T; Borštnar S; Vrhovec I
    Prognostic and predictive value of the urokinase-type plasminogen activator (uPA) and its inhibitors PAI-1 and PAI-2 in operable breast cancer
    2003 ►
  36. Čufer Tanja
    Osnovni principi zdravljenja raka
    2002 ►
  37. Čufer Tanja
    Palliative and supportive care
    2003 ►
  38. Borštnar Simona; Vrhovec Ivan; Čufer Tanja
    Urokinazni aktivator plazminogena, njegovi zaviralci in receptor pri raku dojke - novi napovedni dejavniki poteka bolezni in odgovora na sistemsko zdravljenje
    2003 ►
  39. Škrbinc B; Babič A; Čufer T; Us-Krašovec M
    Cytological grading of breast cancer in Giemsa-stained fine needle aspiration smears
    2001 ►
  40. Pompe-Kirn Vera; Zakotnik Branko; Zadnik Vesna; Anžič Jožica; Auersperg Marija; Budihna Marjan; Cerar Olga; Čufer Tanja; Debeljak Andrej; Eržen Janez; Fras Peter; Hočevar Marko; Jezeršek-Novakovič Barbara; Jančar Boris; Kmetec Andrej; Kragelj Borut; Lindtner Jurij; Majdič Elga; Markovič Saša; Marolt France; Ocvirk Janja; Pretnar Jože; Repše Stane; Rudolf Zvonimir; Sedmak Boris; Sok Miha; Stanovnik Marjeta; Šmid Lojze; Štabuc Borut; Tomšič Radka; Vovk Marjeta; Uršič-Vrščaj Marjetka; Zwitter Matjaž; Žumer-Pregelj Mirjana
    Preživetje bolnikov z rakom v Sloveniji: 1983-1997
    [Cancer patients survival in Slovenia: 1983-1997]
    2003 ►
  41. Biganzoli Laura; Čufer Tanja; Bruning Peter; Coleman Robert E; Duchateau Luc; Rapoport Bernardo; Nooij Marianne; Delhaye Francois; Miles D; Sulkes Aaron
    Doxorubicin-paclitaxel: a safe regimen in terms of cardiac toxicity in metastatic breast carcinoma patients. Results from a European organization for research and treatment of cancer multicenter trial
    2003 ►
  42. Lahajnar-Čavlovič Slavica; Švab Igor; Čufer Tanja; Krčevski-Škvarč Nevenka; Manohin Aleksander; Kersnik Janko; Ažman Drago; Velepič Marina; Logonder Mira; Sonc Monika; Berložnik Magda; Pentek Metka; Vodopivec-Jamšek Vlasta; Tomazin Iztok
    Priporočila za zdravljenje bolečine pri odraslem bolniku z rakom
    2001 ►
  43. Čufer Tanja
    Izguba telesne teže in podhranjenost bolnikov z rakom
    2002 ►
  44. Bergant Damijan; Hočevar Marko; Čufer Tanja
    Karcinom Merklovih celic
    2002 ►
  45. Čufer Tanja
    Odmev na članek o delu razsodišča II. stopnje
    2003 ►
  46. Čufer Tanja; Golouh Rastko; Noč Gorazd; Rudolf Zvonimir; Snoj Marko; Vardijan Rudolf
    Obračun na onkologiji
    2002 ►
  47. Čufer T
    Symptomatic and supportive care in metastatic disease
    2002 ►
  48. Borštnar S; Vrhovec I; Čufer T
    Prognostic value of plasminogen activator inhibitors in breast cancer
    2002 ►
  49. Awada A; Biganzoli L; Čufer T; Beex L; Lohrisch C; Batter V; Hamilton A; Nooij M; Piccart M
    An EORTC-IDBBC phase I study of gemcitabine and continuous infusion 5-fluorouracil in patients with metastatic breast cancer resistant to anthracyclines or pre-treated with both anthracyclines and taxanes
    2002 ►
  50. Biganzoli L; Čufer T; Bruning P; Coleman R; Duchateau L; Calvert AH; Gamucci T; Twelves C; Fargeot P; Epelbaum R; Lohrisch C; Piccart MJ
    Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European organization for research and treatment of cancer 10961 multicenter phase III trial
    2002 ►
  51. Borštnar S; Vrhovec I; Svetič B; Čufer T
    Prognostic value of the urokinase-type plasminogen activator, and its inhibitors and receptor in breast cancer patients
    2002 ►
  52. Čufer Tanja
    Rak dojke
    2001 ►
  53. Biganzoli L; Bonnefoi H; Mauriac L; Čufer T; Kabanga-Ngalula E; Hebert D; Piccart M
    Cyclophosphamide (C) - Epirubicine (E) - Capecitabine (X) combination, CEX: a safe and active regimen in the treatment of locally advanced/inflammatory (LA/I) or large operable (LO) breast cancer (BC). An EORTC-IDBBC study
    2001 ►
  54. Žgajnar J; Hočevar M; Bešić N; Vrščaj M; Pajk B; Čufer T; Jakopin C; Krajc M
    Genetic counceling for hereditary breast and ovarian cancer. Our experience at the Institute of oncology in Ljubljana, Slovenija
    2002 ►
  55. Jagodic M; Vrhovec I; Borštnar S; Matos E; Čufer T
    Prognostic value of different proteolitic factors in primary breast cancer
    2002 ►
  56. Matos E; Vrhovec I; Borštnar S; Jagodic M; Čufer T
    Predictive value of PAI-1 and PAI-2 in breast cancer
    2002 ►
  57. Pajk B; Borštnar S; Vrhovec I; Čufer T
    PAI-1 is independant prognostic factor in the elderly breast cancer patients
    2002 ►
  58. Čufer Tanja
    Nosečnost in rak dojk
    2001 ►
  59. Žgajnar J; Hočevar M; Bešič N; Čufer T; Pajk B; Jakopin C; Vrščaj M; Krajc M
    Genetsko svetovanje za dedni rak dojk in jajčnikov. Izkušnje Onkološkega inštituta v Ljubljani
    2002 ►
  60. Štotl J; Čufer T; Kozjek F; Sonc M
    Comparison of quality of lif of breast cancer patients, treated with two diferent chemotherapeutic schemes
    2002 ►
  61. Bonnefoi H; Biganzoli L; Čufer T; Mauriac L; Hamilton A; Schaefer P; Picart M
    An EORTC phase I study of epirubicin in combination with fixed doses of cyclophosphamide and infusional 5-fu (CEF-infu) as primary treatment of large operable or locally advanced/inflammatory breast cancer
    2001 ►
  62. Look Maxime P; van Putten Wim LJ; Duffy Michael J; Harbeck Nadia; Christensen Ib Jarle; Thomsen Christoph; Kates Ronald; Spyratos Frederique; Fernoe Marten; Čufer Tanja; Borštnar Simona
    Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients
    2002 ►
  63. Čufer T; Vrhovec I; Borštnar S
    Prognostic significance of plasminogen activator inhibitor-1 in breast cancer, with special emphasis on locoregional recurrence-free survival
    2002 ►
  64. Svetic B; Vrhovec I; Kramberger M; Borštnar S; Čufer T
    The influence of different buffers on tumor tissue preparation for biochemical determination of cathepsins D and L
    2002 ►
  65. Thuerlimann B; Price KN; Castiglione M; Lindtner J; Eržen D; Čufer T; Červek J; Cerar O; Zakotnik B; Majdič E; Golouh R; Lamovec J; Jančar J; Vrhovec I; Kramberger M
    Randomized controlled trial of ovarian function suppression plus tamoxifen versus the same endocrine therapy plus chemotherapy: is chemotherapy necessary for premenopausal women with node-positive, endocrine-responsive breast cancer? First results of International breast cancer study group trial 11-93
    2001 ►
  66. Bračko Matej; Us-Krašovec Marija; Čufer Tanja; Lamovec Janez; Zidar Andreja; Goehde Wolfgang
    Prognostic significance of DNA ploidy determined by high-resolution flow cytometry in breast carcinoma
    2001 ►
  67. Bonetti M; Gelber RD; Goldhirsch A; Lindtner J; Eržen D; Majdič E; Štabuc B; Plesničar A; Golouh R; Lamovec J; Jančar J; Vrhovec I; Kramberger M; Cerar O; Šebek S; Novak J; Naglas M; Senčar M; Červek J; Čufer T
    Features that predict responsiveness to chemotherapy and endocrine therapies
    2001 ►
  68. Čufer Tanja
    Dopolnilno zdravljenje
    2001 ►
  69. Dirix L; Piccart MJ; Lohrisch C; Beex L; Nooij M; Cameron D; Biganzoli L; Čufer T; Yague C; Duchateau L
    Efficacy of and tolerance to Exemestane (E) versus Tamoxifen (T) in 1st line hormone therapy (HT) of postmenopausal metastatic breast cancer (MBC) patients (pts): a European orgnisation for the research and treatment of cancer (EORTC breast group) phase II trial with Pharmacia and Upjohn
    2001 ►
  70. Bonnefoi H; Biganzoli L; Mauriac L; Čufer T; Yague C; Hebert D; Piccart M
    An EORTC-IDBBC phase I study of cyclophosphamide (C) and epirubicin (E) in combination with capecitabine (X) (CEX) as primary treatment of locally advanced / inflammatory (LA/I) or large operable (LO) breast cancer (BC)
    2001 ►
  71. Borštnar S; Vrhovec I; Čufer T
    Prognostic value of PAI-1 and PAI-2 combination in primary breast cancer
    2001 ►
  72. Lohrisch C; Paridaens R; Dirix LY; Beex L; Nooij M; Cameron D; Biganzoli L; Čufer T; Yague C; Duchateau L
    Adverse impact on serum lipids of the irreversible aromatase inactivator Aromasin (Exemestane (E)) in 1st line treatment of metastatic breast cancer (MBC): companion study to a European organization of research and treatment of cancer (Breast group) trial with Pharmacias' Upjohn
    2001 ►
  73. Čufer Tanja
    Spoštovani urednik!
    2001 ►
  74. Čufer Tanja
    Nova zdravila za zdravljenje raka
    2001 ►
  75. Čufer Tanja
    Za pravilen nadzor in oskrbo bolnikov ni dovolj le dobra volja...: kako bolje zdraviti raka z zdravili
    2001 ►
  76. Čufer Tanja
    Kaj lahko o raku izvemo na internetu?
    2001 ►
  77. Čufer Tanja
    Nova biološka zdravila za raka
    2001 ►
  78. Jagodic Monika; Čufer Tanja; Zakotnik Branko; Červek Jožica
    Selection of candidates for oral etoposide salvage chemotherapy in heavily pretreated breast cancer patients
    2001 ►
  79. Zwitter M; Čufer T; Wein W
    Gemcitabine and vincristine: an effective outpatient regimen with low myelotoxicity for stage IV non-small cell lung cancer
    2001 ►
  80. Čufer Tanja; Us-Krašovec Marija
    Pomen pretočnocitometrične analize DNA pri načrtovanju zdravljenja karcinoma dojke
    2001 ►
  81. Awada A; Nooij M; Biganzoli L; Čufer T; Beek L; Batter V; Piccart MJ
    A phase I study of continuous infusion 5-fluorouracil (F-intu) in combination with gemcitabine (GEM) in patients (pts) with anthracycline- (A) refractory or A- and taxane- (T) pretreated metastatic breast cancer (MBC)
    2000 ►
  82. Biganzoli L; Čufer T; Fargeot P; Rapoport B; Nooij M; Duchateau L; van Hoorebeeck I; Yague C; Epelbaum R; Piccart M
    Doxorubicin (A)/taxol (T): a safe regimen in terms of cardiac toxicity in the contex of an EORTC multicenter trial
    2000 ►
  83. Biganzoli L; Čufer T; Bruning P; Coleman R; Calvert H; Gamucci T; Twelves C; di Paola E Donato; Duchateau L; Yague C
    Doxorubicin (A) / Taxol (T) versus doxorubicin /cyclophosphamide (C) as first line chemotherapy in metasttaic breast cancer (MBC): a phase III study
    2000 ►
  84. Čufer Tanja
    Sistemsko zdravljenje raka
    2000 ►
  85. Čufer Tanja
    Celovita obravnava raka dojke
    2000 ►
  86. Čufer Tanja
    Rak dojke ni ena bolezen
    2001 ►
  87. Jagodic M; Zakotnik B; Golouh R; Červek J; Čufer T
    Response to oral etoposide in advanced breast cancer: correlation with expression of c-erbB-2 protein
    2000 ►
  88. Borštnar Simona; Vrhovec I; Čufer Tanja
    Prognostic value of urokinase plasminogen activator inhibitors in cytosols from breast cancer patients
    2000 ►
  89. Pajk Bojana; Čufer Tanja; Borštnar Simona; Zakotnik Branko; Us-Krašovec Marija
    Predictive value of DNA ploidy in elderly breast cancer patients treated with tamoxifen
    2000 ►
  90. Čufer Tanja
    Update on breast cancer chemotherapy
    2000 ►
  91. Čufer Tanja; Pfeifer Marija; Vrhovec Ivan; Frangež Robert; Kosec Marjan; Mrhar Aleš; Grabnar Iztok; Golouh Rastko; Vogrinc Sonja; Sikič Branimir Ivan
    Decreased cortisol secretion by adrenal glands perfused with the P-glycoprotein inhibitor valspodar and mitotane or doxorubicin
    2000 ►
  92. Prechtl A; Harbeck N; Thomssen C; Meisner C; Braun M; Untch M; Wieland M; Lisboa B; Čufer T; Graeff H
    Tumor-biological factors uPA and PAI-1 as stratification criteria of a multicenter adjuvant chemotherapy trial in node-negative breast cancer
    2000 ►
  93. Čufer T; Bračko M
    Myeloid metaplasia of the breast
    2001 ►
  94. Serša Gregor; Čufer Tanja; Čemažar Maja; Reberšek Martina; Rudolf Zvonimir
    Electrochemotherapy with bleomycin in the treatment of hypernephroma metastasis: case report and literature review
    2000 ►
  95. Reberšek Martina; Čufer Tanja; Rudolf Zvonimir; Serša Gregor
    Electrochemotherapy with cisplatin of breast cancer tumour nodules in male patient
    2000 ►
  96. Čufer Tanja
    Ali pomeni ohranitev organov tudi boljšo kakovost življenja? Pogovor s prof. dr. Ianom Tannockom
    2000 ►
  97. Reberšek Martina; Čufer Tanja; Rudolf Zvonimir; Serša Gregor
    Electrochemotherapy with cisplatin of breast cancer tumor modules in a male patient
    [Elektrokemoterapija s cisplatinom pri bolniku z rakom dojke]
    2000 ►
  98. Čufer T
    Adjuvant therapy of breast cancer: update
    1999 ►
  99. Kozjek F; Sonc M; Čufer T; Primožič S
    Drug-drug interactions and pseudo double medications in the treatment of oncological patients
    2000 ►
  100. Matos Tadeja; Čufer Tanja; Červek Jožica; Borštnar Simona; Kragelj Borut; Žumer-Pregelj Mirjana
    Prognostic factors in invasive bladder carcinoma treated by combined modality protocol (organ-sparing approach)
    2000 ►

   1 82 182 282 382 482  

New search      Comments      Top of page Institute for Biostatistics and Medical Informatics